Botox neck bands: platysma bands, why and how?
The vertical bands that show on the neck when you clench your teeth are caused by the platysma, a thin neck muscle. Their treatment with botulinum toxin has been approved in the United States since October 2024, but not in France, where it remains off-label. Here is what studies show, and the precautions specific to the neck.
The neck is one of the eleven areas of our guide to botulinum toxin, area by area. This page is about platysma bands: where they come from, what studies show, why treatment is approved in the United States but not in France, and which precautions apply to this area. It does not replace a consultation.
Why is the neck treated?
The platysma is a very thin, sheet-like muscle that spreads under the skin of the neck from the jaw. When it contracts, it can form vertical bands, sometimes called "neck cords", connecting the jaw and the neck1. Researchers use the term "platysma prominence" for all the visible effects of its contraction: neck bands and a less defined jawline2.
Botulinum toxin temporarily relaxes the platysma fibres injected just under the skin, which softens these bands2. An Italian expert consensus published in 2026 identifies three indications for this muscle: platysma bands, jawline contour and skin texture3. Platysma bands already appeared in an international consensus from 2010, written by an expert board convened around one manufacturer’s product4.
What the toxin does not do: it does not treat excess skin on the neck or fat under the chin, and it does not treat horizontal lines related to skin quality in the same way as muscle bands.
When is the toxin used?
In France, there are no official criteria, since no label provides for this area. In the United States, the FDA approval covers the temporary improvement in the appearance of moderate to severe vertical bands connecting the jaw and neck, in adults1. The phase 3 trial that supported it involved adults with moderate to severe platysma prominence2.
The contraindications in the labels apply whatever the area: allergy to the toxin or to a component of the product, a generalised disorder of the muscles and of the junction between nerve and muscle (myasthenia gravis, Lambert-Eaton syndrome), an infection at the injection site5,6. For the neck, one precaution matters particularly: the labels advise against injection in people with a history of swallowing problems or aspiration (food or liquid going down the wrong way)5,6. Pregnancy and breastfeeding are also situations in which treatment is not recommended5,6.
Which toxin for the neck?
| Toxin | Status in France |
|---|---|
| Long-acting botulinum toxin (type A) | No aesthetic indication for this area in the SmPCs in force in France: off-label use, to be discussed with your doctor |
| Short-acting botulinum toxin (serotype E) | No aesthetic indication for this area in the SmPCs in force in France: off-label use, to be discussed with your doctor |
Approved in the United States for neck (platysma) bands since October 2024 (a type A product), not in France.
The type A toxins approved for aesthetic use in France cover frown lines and, depending on the product, crow’s feet and forehead lines6. None provides for the neck. The short-acting botulinum toxin (serotype E) is approved for frown lines only, in the European Union and in Canada5,7. In France, any injection in this area is therefore off-label.
The situation is different in the United States: in October 2024, the FDA approved a type A toxin for moderate to severe platysma bands in adults1. This approval does not apply in France.
Is it right for me?
Your doctor will look at your neck at rest and when you clench your teeth, the quality of your skin and your jawline. They will ask about any difficulty swallowing, choking episodes or breathing problems, which call for caution5,6. They will take into account your medical history, your treatments and any pregnancy plans.
The neighbouring areas are covered on the pages about the masseter and jaw and the orange peel chin.
Questions to ask your doctor: is this treatment off-label in France? Are my bands caused by the muscle? Which signs should make me seek urgent care? How long should the effect last, in your experience?
Onset and duration
No French label gives an onset or duration for this area. In the phase 3 trial, the main effect was assessed on day 14: 32.3% of treated people had reached a minimal or mild grade with an improvement of at least two grades, compared with 1.9% on placebo2. Participants were followed for 120 days after a single session2; the abstract does not state how long the effect lasted.
How these timelines work in general is explained on the page about how long botulinum toxin takes to work.
What are the risks in this area?
The neck is close to the muscles used for swallowing and speaking. All the labels point out that the effect of the toxin can, in some cases, be seen beyond the injection site, with muscle weakness, swallowing or speech problems, or even breathing difficulties5,6. These problems require immediate medical attention5.
In the phase 3 trial on neck bands, side effects were as frequent with the toxin as with placebo, and no swallowing problems or muscle weakness were reported2. This trial evaluated a single session, and several of its authors were employees of or consultants to the manufacturer2.
If you feel any discomfort after a neck injection, the page on the neck after an injection explains how to recognise a stiff neck or difficulty swallowing, and when to seek urgent care.
Key points
- Neck bands are caused by the platysma, a thin muscle under the skin1,2.
- Treatment approved in the United States since October 2024 for a type A toxin, off-label in France1,6.
- Difficulty swallowing, speaking or breathing after the injection requires immediate medical attention5.
- Tell your doctor about any history of swallowing problems before the injection.
Frequently asked questions
What are platysma bands?
The platysma is a very thin muscle lying just under the skin of the neck. When it contracts, it can form vertical bands connecting the jaw and the neck, and blur the jawline1,2. These bands are more visible when you clench your teeth or tense your neck. Their treatment with botulinum toxin is described by expert consensus documents3,4.
Is treating the neck with botulinum toxin approved in France?
No. No French label provides for this area: the type A toxins approved for aesthetic use cover frown lines and, depending on the product, crow’s feet and the forehead6, and the short-acting toxin covers frown lines only5. In the United States, the FDA approved a type A toxin in October 2024 for moderate to severe platysma bands in adults1.
Can a neck injection make swallowing difficult?
This is a known risk of botulinum toxin in general: its effect can, rarely, spread beyond the injection site and cause swallowing, speech or breathing problems, which require immediate medical attention5,6. In the phase 3 trial on neck bands, no swallowing problems were reported2. Always tell your doctor about any past difficulty swallowing.
Sources
- 1.Manufacturer press release (AbbVie) on the FDA approval for neck (platysma) bands, 18 October 2024 (opens in a new tab) — AbbVie (manufacturer)
- 2.Fabi S. et al., type A botulinum toxin and neck (platysma) bands: placebo-controlled phase 3 trial, Journal of the American Academy of Dermatology, 2025 (opens in a new tab) — Journal of the American Academy of Dermatology
- 3.Fundarò S. et al., Italian consensus and review on treating the lower face muscles with type A botulinum toxin, Toxins, 2026 (opens in a new tab) — Toxins (MDPI)
- 4.Ascher B. et al., international consensus recommendations on type A botulinum toxin in aesthetics, part II: middle and lower face, neck and chest, Journal of the European Academy of Dermatology and Venereology, 2010 (expert board convened around one manufacturer’s product) (opens in a new tab) — Journal of the European Academy of Dermatology and Venereology
- 5.Summary of product characteristics of the serotype E botulinum toxin approved in the European Union (EPAR annex I) (opens in a new tab) — European Commission (Union Register of medicinal products)
- 6.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 68150775) (opens in a new tab) — French public medicines database (BDPM)
- 7.Canadian product monograph of the serotype E botulinum toxin (authorization date: 2026-06-22) (opens in a new tab) — Health Canada